Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Safety Study of EB-101 in Dystrophic Epidermolysis Bullosa
NCT05725018Phase 3Active, not recruiting
- Sponsor
- Abeona Therapeutics Inc.
- Start
- Apr 2023
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of prademagene zamikeracel in dystrophic epidermolysis bullosa (DEB), sponsored by Abeona Therapeutics Inc.. Started Apr 2023; status: active, not recruiting.
02
Drugs
prademagene zamikeracel
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT05725018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725018.